Georgiamune is a company focused on reprogramming immune responses to fight cancer and autoimmune diseases by regulating signaling pathways to restore immune homeostasis.

Georgiamune

Georgiamune Inc. is a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. Unique approaches to re-establishing immune balance and groundbreaking scientific discoveries have led to the development of pioneering immune therapeutics for cancer and autoimmune diseases.

Parker Institute for Cancer Immunotherapy

Mubadala Capital Ventures

Verition Fund Management

General Catalyst

Bioventures Investors

Catalio Capital Management

Alexandria Venture Investments

Lauder Partners

Georgiamune Inc.

We’re incredibly proud our CEO and Founder Samir Khleif was named a winner of the prestigious EY Entrepreneur of the Year Awards for his pioneering work and groundbreaking innovations in novel biology discoveries. Congratulations to the other finalists and winners! 
 
To view all winners and learn more about the award, visit: https://go.ey.com/4eHrqW7 #EYEntrepreneurOfTheYear #EYAwards #EYEOY #novelbiology

Big news from our team today! We're excited to announce that GIM-531 has received IND clearance from the FDA. GIM-531 is a first-in-class oral treatment that selectively targets T-regulatory cells, while sparing other immune cells like CD4 and CD8. That's in addition to GIM-122, our first-in-class, dual-functioning antibody, which is in human clinical trials. 
 
We're proud to help propel novel science, and are another step closer to reprogramming immune signaling pathways to redirect the immune system to fight cancer and autoimmune diseases. Learn more: https://lnkd.in/gjtA5pRP 
#clinicaltrials #FDAclearance #cancer #firstinclass #noveldrugs

Founder and CEO Samir Khleif sat down with RJ Lumba on the Great Entrepreneurs Podcast. Hear Dr. Khleif shed light on his background, the origin of Georgiamune and our mission to reprogram immune signaling pathways to redirect the immune system to fight diseases. 

https://lnkd.in/gu7UMzsn 
#biotech #hiring

At Georgiamune Inc., we’re reprogramming immune signaling pathways to redirect the immune system to fight diseases. We’re excited to announce the clearance of our IND for our lead compound, GIM-122, a first-in-class, dual functioning monoclonal antibody. We’re also extremely grateful to the top-tier investors who helped us raise $75M in our Series A financing round. Learn more about our mission, our science and our team at www.georgiamune.com

#immunotherapy #immunooncology #biotech

Georgiamune is honored to be included on BioSpace’s prestigious List of the Top 30 Life Sciences Trailblazers for 2024! We are looking forward to 2024 as we continue to deliver novel drugs to restore immune homeostasis to fight cancer and autoimmune diseases. 

Learn more about our mission, our science, and our team at www.georgiamune.com.

#oncology #autoimmune #lifesciences #biotech

Our CEO Samir Khleif sat down with Rebecca Torrence from Business Insider to share progress on GIM-122's clinical trial, our first-in-class pipeline, and our $75 million in Series A funding, co-led by General Catalyst and Parker Institute for Cancer Immunotherapy.

Read the full article to learn how our novel biology is pioneering breakthroughs in cancer and autoimmune drugs: https://bit.ly/3vsRZMR #novelbiology #Georgiamune

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jul 12, 2024 12:00 AM	09aff22f
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 12, 2024 2:14 PM	e4b23326
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	93dde699
crunchbase profile	general
li profile	general	Jul 12, 2024 12:00 AM	e1397a51
translate crunchbase fundingrounds	general
peers	general	Jul 12, 2024 12:00 AM	ac4845a5
news basic	general	Jul 12, 2024 12:00 AM	b8b4c9c0
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:GEORGIAMUNE

Georgiamune